Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585660 · ClinicalTrials.gov registry record · NA
Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
A NA study of Prostate Cancer, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT03585660: Completed NA study of Prostate Cancer, sponsored by University of Chicago.
NCT03585660 is a NA study of Prostate Cancer that has completed, run by University of Chicago. The registered enrollment target is 106 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03585660, a NA study of Prostate Cancer, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the proposed research is to test and validate a Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).
Primary Outcome
The accuracy of HM-MRI is defined as the proportion of correctly diagnosed participants for prostate cancer using HM-MRI.
Conditions Studied
Interventions
- PROCEDURE Diagnostic MRI
- PROCEDURE Diagnostic Prostate Biopsy
- DEVICE Risk Map DSS tool
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2018-08-28 |
| Est. Completion | 2023-11-06 |
| Phase | NA |
What the finished NCT03585660 record still lists
NCT03585660 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Diagnostic MRI is the first listed.
NCT03585660 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03585660 about?
NCT03585660 is a clinical study titled "Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy". The purpose of the proposed research is to test and validate a Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).
What is the current status of trial NCT03585660?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2018-08-28. Estimated completion is 2023-11-06.
What conditions does trial NCT03585660 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03585660?
The interventions under investigation include: Diagnostic MRI (PROCEDURE), Diagnostic Prostate Biopsy (PROCEDURE), Risk Map DSS tool (DEVICE).
Who is sponsoring clinical trial NCT03585660?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03585660 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03585660's enrollment target sits among peer trials
106 325th of 735 higher than 411 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI